Sanofi: Sanofi's Wayrilz approved in the EU as the first BTK inhibitor to treat immune thrombocytopenia

Sanofi's Wayrilz approved in the EU as the first BTK inhibitor to treat immune thrombocytopenia Novel treatment targets BTK through multi-immune modulation to help address the underlying causes of ITP ...

Akari Therapeutics Plc: Akari Therapeutics Initiates GMP Manufacturing of AKTX-101 ADC Program to Support Phase 1 First-in-Human Clinical Trial

Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel payloads, today ...

Biohaven Provides Update From Phase 2 Proof-of-Concept Study with BHV-7000 in Major Depressive Disorder

Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, ...

Best BPC-157 Oral Supplements: ProHealth's Triple-Tested Formula Examined as Peptide Quality Verification Becomes Consumer Priority Heading Into 2026

Third-Party Lab Testing, Bioavailability Questions, and Regulatory Status ExaminedCARPINTERIA, Dec. 23, 2025 (GLOBE NEWSWIRE) ...